Immutep (IMMP) AI Stock Analysis

• Market Cap: $248.28M
• Dividend Yield: N/A
• Average Volume (3M): 85.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: 15.14%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 146,786,480
• 10 Day Avg. Volume: 68,794
• 30 Day Avg. Volume: 85,076
• PEG Ratio: -1.13
• Price to Book (P/B): 2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 601.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: $1.50 ▼(-12.28%Downside)

Immutep's overall stock score reflects its financial challenges typical of a biotech firm in development, with significant profitability issues and mixed technical indicators. While the balance sheet provides financial stability, negative valuation metrics due to ongoing losses limit appeal. The absence of recent earnings call data and corporate events results in a score driven primarily by financial performance and technical analysis.

Positive Factors

Clinical Trials

Immutep reported positive response data from the ongoing P1 INSIGHT-003 study evaluating the triple combination of eftilagimod, chemotherapy, and Keytruda in metastatic non-small cell lung cancer, demonstrating a 60.8% overall response rate and a 90.2% disease control rate.

Financial Stability

The company has a strong cash position, expecting to be funded through the end of 2026.

Regulatory Progress

Immutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.

Negative Factors

Historical Comparison

In the TPS <50% subgroup, the triple combo demonstrated a 59.6% overall response rate versus 40.8% for historical control, indicating room for improvement compared to historical benchmarks.

Regulatory Approval Uncertainty

If the INSIGHT-003 data holds up in the larger TACTI-004 study, the probability of approval in first-line favoring Immutep is expected to increase, suggesting current uncertainty in regulatory approval.

Immutep Business Overview & Revenue Model

Company Description

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

How the Company Makes Money

Immutep makes money primarily through licensing agreements, collaborations, and milestone payments related to its proprietary technology and product candidates. The company partners with pharmaceutical and biotechnology companies to advance its product pipeline, receiving upfront payments, research funding, and potential future royalties from successful commercialization. Additionally, Immutep may generate revenue through government grants and research funding aimed at supporting the development of new treatments. These strategic partnerships and funding opportunities are crucial for Immutep's financial sustainability and growth in the competitive biotech industry.

Immutep Financial Statement Overview

Summary

Immutep faces profitability challenges with ongoing operational losses and negative margins, typical of biotech firms in development. Despite this, its strong equity position and low leverage provide financial stability, supported by significant cash reserves.

Income Statement

Immutep's income statement reveals significant challenges with profitability. The company has consistently reported negative net income and EBIT, indicating ongoing operational losses. Revenue growth has been inconsistent, with a recent increase from 2023 to 2024, but overall revenues remain low. Gross profit margins are negative, reflecting high costs relative to revenue. The biotechnology industry often faces long development cycles and high R&D costs, contributing to these financial pressures.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicating financial stability. The company maintains a low debt-to-equity ratio, suggesting prudent financial management and low leverage. However, the negative net income impacts return on equity, which remains negative. The high cash reserves provide a buffer for ongoing operations and potential investments.

Cash Flow

Immutep's cash flow statement highlights substantial negative free cash flow, reflecting cash burn typical for biotech companies in development phases. Operating cash flow is negative, indicating cash outflows from core operations. However, the company has successfully raised financing, as seen in positive financing cash flow, supporting its liquidity position. The free cash flow to net income ratio is unfavorable due to persistent losses.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	3.84M	3.51M	170.37K	3.97M	7.49M
Gross Profit	-37.70M	1.44M	-1.89M	1.90M	-14.99M
EBITDA	-44.54M	-39.57M	-31.87M	-17.77M	-13.46M
Net Income	-42.72M	-39.90M	-32.21M	-29.90M	-13.47M
Balance Sheet
Total Assets	201.58M	147.45M	102.17M	82.03M	46.60M
Cash, Cash Equivalents and Short-Term Investments	181.88M	123.42M	80.00M	60.13M	26.32M
Total Debt	1.59M	1.23M	1.73M	2.82M	9.05M
Total Liabilities	12.06M	10.98M	8.09M	8.76M	13.30M
Stockholders Equity	189.52M	136.47M	94.08M	73.27M	33.30M
Cash Flow
Free Cash Flow	-35.75M	-35.93M	-30.25M	-17.66M	-10.86M
Operating Cash Flow	-34.82M	-35.88M	-30.23M	-17.64M	-10.84M
Investing Cash Flow	-21.02M	-31.00K	-22.91K	-15.60K	-19.35K
Financing Cash Flow	95.18M	76.04M	50.33M	52.68M	20.48M

Immutep Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Positive. The current price of 1.71 is above the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.78, and below the 200-day MA of 1.88, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.70 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMMP.

Immutep Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$414.85M	―	-41.31%	―	―	-7.93%
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.81%	16.35%	0.03%
IMMP	47 Neutral	$248.28M	―	-31.16%	―	―	15.14%
AVIR	47 Neutral	$287.55M	―	-30.47%	―	―	-22.66%
ATXS	44 Neutral	$336.91M	―	-32.89%	―	―	27.92%
YMAB	44 Neutral	$195.22M	―	-29.93%	―	3.38%	-36.40%
ITOS	41 Neutral	$392.69M	―	-23.68%	―	―	14.60%